Tapasya Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.50 M
- Revenue Growth -0.93%
- Profit Growth 30.71%
- Ebitda 220.35%
- Net Worth 26.65%
- Total Assets 16.84%
About Tapasya Pharma
Tapasya Pharma Private Limited (TPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 August 2016 (Eight years and six months 23 days old ). Its registered office is in Aurangabad, Maharashtra, India.
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Anupama Patil, Mohan Sonawane, Sumedha Dharurkar, and Two other members serve as directors at the Company.
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U36990MH2016PTC284353
- Company No.
284353
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Tapasya Pharma?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anupama Patil  | Director | 02-Aug-2016 | Current |
| Mohan Sonawane | Director | 02-Aug-2016 | Current |
| Sumedha Dharurkar | Director | 02-Aug-2016 | Current |
| Mayur Sonawane | Director | 02-Aug-2016 | Current |
| Tapasya Patil | Director | 08-Sep-2023 | Current |
Financial Performance of Tapasya Pharma.
Tapasya Pharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 0.93% decrease. The company also saw a substantial improvement in profitability, with a 30.71% increase in profit. The company's net worth Soared by an impressive increase of 26.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tapasya Pharma?
Unlock access to Tapasya Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Mar 2023 | Others | ₹0.50 M | Open |
How Many Employees Work at Tapasya Pharma?
Unlock and access historical data on people associated with Tapasya Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tapasya Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tapasya Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.